Date: 17th April 2019

**Description of product affected**

- Labetalol is a non-selective beta-blocker with additional alpha blocking properties.
- It is licensed for the treatment of mild to severe hypertension, hypertension in pregnancy and angina pectoris with existing hypertension.¹
- **Labetalol is primarily used for hypertension in pregnancy.**

**Background**

- Mylan and Recipharm are the two UK suppliers of labetalol tablets.
- DHSC have been informed there is going to be a supply issue affecting all strengths of labetalol tablets until early-mid May.
  - Labetalol 50mg tablets,
  - Labetalol 100mg tablets,
  - Labetalol 200mg tablets,
  - Labetalol 400mg tablets.
- Supply of labetalol IV is not affected.

**Alternative agents and management options**

- In the first instance the patient should be encouraged to try several pharmacies in order to fulfil the prescription. The pharmacy should support patients to ring other pharmacies in advance of attending to ascertain availability.
- Patients who do not have sufficient supplies to last until mid-May and who are unable to obtain supplies of labetalol will need to be switched to an appropriate alternative treatment during this time.
- The decision about what to do will need to be individualised to each patient.
- **The clinical management plan for pregnant and lactating patients will be different to patients who are not pregnant or lactating.**
- Prescribers should be aware that **NO NEW PATIENTS** should be commenced on labetalol during this time as there are currently very limited stocks available.
Hypertension and angina (excluding pregnancy or lactating patients)

- Table 1 demonstrates which other beta-blockers are licensed for hypertension and angina.
- The choice of beta-blocker will depend on co-morbidities, local recommendations (see below) and cost. Where possible, prescribe a drug that is taken only once a day and prescribe generically.2
- Within primary care the formulary choice which should be considered the 1st line beta-blocker for hypertension is Bisoprolol.

| Table 1: Other commonly used beta-blockers licensed for hypertension and angina |
|------------------|------------------|------------------|
|                  | Hypertension     | Angina           |
| Atenolol         | ✓                | ✓                |
| Bisoprolol       | ✓                | ✓                |
| Propranolol      | ✓                | ✓                |

Please note – the manufacturers of both carvedilol and metoprolol have indicated that they cannot support the market with the additional demand and so have not been included in the above table.

Dose equivalence and conversion (excluding pregnancy and breastfeeding)

- There is no definitive guidance for dose conversion between beta-blockers and clinical judgement will be required in considering where the labetalol dose sits within the dose range of the alternative beta-blocker.

- When switching patients to alternate beta-blockers, blood pressure, pulse rate, and signs and symptoms of the underlying disorder should be monitored to guide dosing. Table 2 provides dose ranges for some commonly used beta-blockers described above.

- It is important to involve any patients (and their carers, as appropriate) in the discussion regarding any planned change to their medication BEFORE making the change.

- If any of the recommendations are not clinically acceptable or there is any uncertainty about what to do or how to do it then management options should be discussed with the responsible consultant specialist depending on the indication.

Table 2: Licensed target dose ranges for adults for various indications (dose adjustments may be required based on clinical response, co-morbidities e.g. renal impairment and age)

<table>
<thead>
<tr>
<th></th>
<th>Labetalol</th>
<th>Bisoprolol</th>
<th>Atenolol</th>
<th>Propranolol</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypertension</strong></td>
<td>100-200mg</td>
<td>5-20mg OD</td>
<td>25-100mg</td>
<td>40mg BD or TDS, max 320mg per day</td>
</tr>
<tr>
<td></td>
<td>BD, increased if necessary, to 400mg BD</td>
<td>OD</td>
<td>OD</td>
<td></td>
</tr>
<tr>
<td><strong>Angina</strong></td>
<td>5-20mg OD</td>
<td>50-100mg OD or 50mg BD</td>
<td>40mg BD or TDS, max 240mg per day</td>
<td></td>
</tr>
<tr>
<td>(co-existing with hypertension)</td>
<td>100 -200mg BD, increased if necessary, to 400mg BD</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Hypertension in pregnancy

- NICE guidelines state that where clinically appropriate, labetalol is recommended as the first line antihypertensive treatment for hypertension in pregnancy.
- NICE guidelines recommend nifedipine or methyldopa as alternatives to labetalol for hypertension in pregnancy considering the side effect profiles.3
- Nifedipine is second line choice after labetalol.3,4
- Use a modified release preparation of nifedipine, usually a twice daily (MR) preparation.4,5 In primary care the twice daily, modified release preparation of nifedipine (MR) formulary choice is Tensipine MR which is available in a 10mg or 20mg strength (Thornton & Ross have confirmed availability).
- If clinically appropriate, start nifedipine on a low dose: nifedipine 10mg MR twice a day, and if necessary, increase to 20mg MR twice a day, then to 30mg MR twice a day and possibly up to 40mg MR twice a day.5
- Third line treatment is methyldopa but it is less well tolerated with increased side effects such as sedation at higher doses.3,5
- Methyldopa is contraindicated in depression.6
- Nifedipine and methyldopa are not licensed specifically for hypertension in pregnancy.6,7
- Expert opinion suggests that if switching from labetalol to nifedipine, labetalol 300mg tds is considered equivalent to nifedipine 20mg MR bd.
- Careful monitoring would be needed with escalation of dose depending on patient response, and it is important to bear in mind that non-response may represent worsening hypertension rather than a non-equivalent dose.
- When switching patients to alternate treatment, blood pressure, pulse rate, and signs and symptoms of the underlying disorder should be monitored to guide dosing.
- If any of the recommendations are not clinically acceptable or there is any uncertainty about what to do or how to do it then management options should be discussed with the responsible consultant specialist.

Hypertension in lactation

- It is important that women are managed on an individual basis in consultation with a specialist, if appropriate, considering patient-specific clinical conditions, including the health and prematurity of the infant.
- The UK Medicines Information (UKMi) Drugs In Lactation Advisory Service suggests the following potential management options8 for hypertension in lactation:
  - Angiotensin-converting enzyme (ACE) inhibitors: Captopril and Enalapril are considered to be compatible with breastfeeding but monitoring of infants, especially premature and newborn for hypotension if exposed to an ACE inhibitor while breastfeeding. These are also recommended by NICE.3
  - Beta-blockers: Propranolol is considered to be the beta-blocker of choice in breastfeeding. It is important to monitor breastfed infants for signs of beta blockade especially bradycardia.
  - Calcium-channel blockers: Nifedipine is considered compatible with breastfeeding and is recommended by NICE. It is important to monitor the infant for adverse effects.
Centrally acting antihypertensives: Methyldopa is considered compatible with breastfeeding but is NOT recommended by NICE for use in the postnatal period due to the risk of depression.

- If any of the recommendations are not clinically acceptable or there is any uncertainty about what to do or how to do it then management options should be discussed with the responsible consultant specialist.

References

1. RPH Pharmaceuticals AB. Trandate (labetalol) 200mg film coated tablets. SPC, date of revision of the text, 8 February 2019: https://www.medicines.org.uk/emc/product/9168
5. Personal communication, Royal College Obstetricians and Gynaecologists, 04 April, 2019.
7. Chiesi. Adipine (nifedipine) 20mg MR tablets. SPC, date of revision of the text, July 2016: https://www.medicines.org.uk/emc/product/7801
9. Labetalol 100mg film-coated tablets SPC (Mylan); DOR = 19/01/2005
10. Bisoprolol 10mg film-coated tablets SPC (Accord Healthcare Ltd); DOR = 31/05/2014
11. Atenolol Tablets BP 25mg SPC (Accord-UK Ltd); DOR = 14th April 2017
12. Propranolol 40mg film-coated tablets SPC (Accord Healthcare Limited); DOR = 14/06/2018
13. Metoprolol Tartrate 50 mg tablets SPC (Accord Healthcare Ltd); DOR = 20/10/2017

Acknowledgements
Jane Bass, Senior Pharmacist, Women's Services, Guy's and St Thomas' NHS Foundation Trust
Vanessa Chapman, Director, Trent Medicines Information Centre & the UK Drugs in Lactation Advisory Service
Laura Kearney, Regional Principal Medicines Information Pharmacist, Trent and Leicestershire Medicines Information Centre & UK Drugs in Lactation Advisory Service

Original document prepared by:
Hina Radia and Diane Bramley, London and South East Regional Medicines Information, Guy’s and St Thomas’ NHS Foundation Trust, 17 April 2019; email: medicinesinformation@gstt.nhs.uk

Document modified by and for all correspondence please contact:
Cambridgeshire and Peterborough Clinical Commission Group, Medicines Optimisation Team. 17 April 2019; email: CAPCCG.prescribingpartnership@nhs.net
Disclaimer: The content of this memo may not reflect national guidance. Some of this memo is based on clinical opinion from practitioners. Users should bear this in mind. Any decision to prescribe off-label must take into account the relevant GMC guidance and governance procedures for unlicensed medicines. Prescribers are advised to pay particular attention to the risks associated with using unlicensed medicines or using a licensed medicine off-label. As with all prescribing, the prescriber is medically and legally responsible for the prescriptions they sign and for their decisions and actions when they supply and administer medicines or authorise or instruct others to do so.